NCT05981703

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 217 (estimated)
• Sponsor: BeOne Medicines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

Detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Conditions

• Advanced Solid Tumor
• Solid Tumor

Interventions

Type	Name	Description
DRUG	BGB-26808	Planned doses administered orally as a tablet daily.
DRUG	Tislelizumab	Planned doses administered by intravenous infusion.
DRUG	Chemotherapy	Administered in accordance with relevant local guidelines and/or prescribing information.

Timeline

• Start date: 2023-09-21
• Primary completion: 2027-09-30
• Completion: 2027-09-30
• First posted: 2023-08-08
• Last updated: 2026-03-19

Locations

26 sites across 4 countries: United States, Australia, China, New Zealand

Regulatory

• FDA-regulated drug study